Thus, although contamination by nontumor tissue may have led us to overlook some additional potential biomarkers, it does not affect our conclusions about the involvement of CDK4 and filamin A in sensitizing tumour cells to paclitaxel. This evidence concerns the gene CDK4 and neoplasm.